As we envision a post-COVID-19 world, how will the model for biomedical innovation change? What lessons have been learned? Was this pandemic a once-in-a-lifetime event or should organizations begin to weave pandemic planning into their business and operations strategies? Panelists will discuss these and other related questions.

Moderator: Janet Wu, Bloomberg
Mike Mahoney, CEO, Boston Scientific
Bernd Montag, PhD, CEO, Siemens Healthineers

свернуть